Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May;17(5):621-625.
doi: 10.1080/17425247.2020.1738380. Epub 2020 Mar 11.

Advancing human in vitro pulmonary disease models in preclinical research: opportunities for lung-on-chips

Arbel Artzy-Schnirman  1 , Claus-Michael Lehr  2   3 , Josué Sznitman  1
Affiliations
Editorial

Advancing human in vitro pulmonary disease models in preclinical research: opportunities for lung-on-chips

Arbel Artzy-Schnirman et al. Expert Opin Drug Deliv. 2020 May.
No abstract available

Keywords: Preclinical research; lung diseases; microfluidics; organ-on-chips; respiratory therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

CM Lehr is co-founder, scientific advisor and shareholder of PharmBioTec GmbH, Saarbrücken, Germany.

Figures

Figure 1
Figure 1
Schematic of preclinical in vitro research tools in respiratory medicine. Traditional assays include the use of petri dishes where cell cultures are grown under submerged conditions. The introduction of filter inserts permits cell cultures (e.g. epithelium, co-cultures, etc.) at the air-liquid interface (ALI), as well as growing endothelial cells on the basal side of the membrane. With the introduction of lung-on-chip platforms, ALI-based cultures can now include an array of physiological cues more closely in line with the innate pulmonary milieu.
Figure 2
Figure 2
Recent examples of lung-on-chips modeling respiratory diseases include an asthma model [27], pulmonary edema [40] and a COPD model [41], as well as most an airway-on-chip study on epithelial and smooth muscle cell interactions in the pathogenesis of chronic lung diseases [42]. By and large, most microfluidic in vitro designs still consist of simple, straight channels featuring an alveolar capillary barrier (ACB) model made of co-cultures of epithelial and endothelial cells grown above and below a porous membrane, respectively.
See this image and copyright information in PMC

References

    1. Hittinger M, Juntke J, Kletting S, Schneider-Daum N, de Souza Carvalho C, Lehr CM. Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models. Adv Drug Deliv Rev. 2015;85:44–56. doi: 10.1016/j.addr.2014.10.011. - DOI - PubMed
    1. Hittinger M, Schneider-Daum N, Lehr CM. Cell and tissue-based in vitro models for improving the development of oral inhalation drug products. Eur J Pharm Biopharm. 2017;118:73–78. doi: 10.1016/j.ejpb.2017.02.019. - DOI - PubMed
    1. Prakash YS, Halayko AJ, Gosens R, Panettieri RA, Camoretti-Mercado B, Penn RB, Aiyar R, Ammit A, Berkman N, Bond R, et al. An official American thoracic society research statement: Current challenges facing research and therapeutic advances in airway remodeling. Am J Respir Crit Care Med. 2017;195:e4–e19. doi: 10.1164/rccm.201611-2248ST. - DOI - PubMed
    1. Barnes PJ, Bonini S, Seeger W, Belvisi MG, Ward B, Holmes A. Barriers to new drug development in respiratory disease. Eur Respir J. 2015;45:1197–1207. doi: 10.1183/09031936.00007915. - DOI - PubMed
    1. Wisnivesky J, De-Torres JP. The global burden of pulmonary diseases: Most prevalent problems and opportunities for improvement. Ann Glob Heal. 2019;85:1–2. doi: 10.5334/aogh.2411. - DOI - PMC - PubMed

Publication types

LinkOut - more resources